Home › Funds › Frazier Life Sciences Management, L.P. › RLAY
Frazier Life Sciences Management, L.P. position in RLAY
RELAY THERAPEUTICS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 1,015,693 shares of RLAY (RELAY THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$19.0M, representing 0.41% of its reported portfolio and ranking #34 among its reported holdings. Frazier Life Sciences Management, L.P. first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s RLAY position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in RLAY in Q2 2026 at 1,015,693 shares (US$19.0M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.02M | $19.00M | New |
About RLAY and 13F data
RLAY (RELAY THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Commodore Capital LP 12.00M sh · $224.52M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- Bellevue Group AG 6.19M sh · $115.74M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Siren, L.L.C. 3.65M sh · $68.29M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Spruce Street Capital LP 2.98M sh · $55.83M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held RLAY?
Frazier Life Sciences Management, L.P. has disclosed RLAY holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Frazier Life Sciences Management, L.P.'s current position in RLAY?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.02M shares of RLAY (RELAY THERAPEUTICS INC), valued at $19.00M, representing 0.41% of its reported portfolio and ranking #34.
Has Frazier Life Sciences Management, L.P. been buying or selling RLAY?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. newly opened its position in RLAY.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.